Supporting research to better understand pancreatic cancer with the goal of improving outcomes for patients.
Each year, more than 350,000 people worldwide are diagnosed with pancreatic cancer – one of the deadliest cancers – with the majority of cases diagnosed in late stage. Despite advances in therapy over the past two decades that have led to doubled 5-year survival rates, pancreatic cancer 5-year survival is still only in the single digits – 8% – due to the complex nature of the disease and lack of symptoms until the disease has progressed.
Celgene is committed to better understanding pancreatic cancer with the goal of improving outcomes for patients. As a leader focused on helping patients with particularly challenging cancers with limited treatment options, we remain committed to delivering new and better options for these patients through our deep scientific expertise.
Advocacy & Collaboration
Learn about the various organizations that support patients with pancreatic cancer.
Celgene is dedicated to offering support to patients with pancreatic cancer and those that care for them.
Visit BolderScience.com to learn more about the latest research in pancreatic cancer.
Celgene is committed to delivering new options for patients with pancreatic cancer.
Check out these resources